ALLURION TECHNOLOGIES INC (ALUR)
OTCHealth CareMedical - DevicesSnapshot 2026-09-04
$1.12+1.82%
Close 2026-09-04 · 1-day change
OTCHealth CareMedical - DevicesSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Allurion aims to regain NYSE listing compliance soon. It has FDA approval for its gastric balloon system. The company is cutting costs and improving operating income. Operating losses shrank from $6.3M to $3.7M in recent quarters.
The company lost key board members recently. It faces delisting risks and legal issues. Operating losses remain high and cash flow is weak. The stock price has dropped nearly 40% from its high.
The market prices in a weak outlook with implied negative growth. Our fair value is $2.33, reflecting the company's loss-making status and risks.
Breaks if: Fails to grow market share or revenue from FDA-approved product in 2026
Breaks if: Operating income worsens beyond -$3.7M in 2026-Q1
Breaks if: Fails to regain NYSE compliance by end of 2026
Advance plan to regain compliance with NYSE listing standards including a 1-for-15 reverse stock split and engagement with national exchanges.
Stated as a priority in 2 quarters including 2025-Q4 and 2026-Q2. Management initiated a 1-for-15 reverse stock split in 2026-Q2 to support regaining NYSE listing compliance after receiving a delisting notice in 2025-Q4. Revenue declined from $5.58M in 2025-Q1 to $2.95M in 2026-Q1, reflecting challenges. The trajectory shows active regulatory efforts but financials indicate limited progress.
“Allurion advances plan to re-list including a 1-for-15 reverse stock split to support regaining NYSE compliance.”
“Received NYSE delisting notice and began efforts to regain compliance with listing standards.”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on regaining compliance and improving operating income. The current thesis state is mixed, as recent financial performance has been neutral and management has faced volatility.
The valuation suggests that ALUR is seen as cheap compared to its peers, though there is an expectations gap indicating that the market is not fully optimistic about its recovery. The current market sentiment reflects a justified valuation without significant fragility.
Fundamentally, ALUR's trajectory may remain challenged due to ongoing losses and mixed results in revenue. Management's focus on FDA approval and improving operating income shows potential for progress, but recent declines in revenue indicate risks.
The long-term thesis hinges on management's ability to regain NYSE compliance, secure FDA approval for key products, and improve overall financial performance. Additionally, broader sector trends and performance of major healthcare players will be critical indicators.
In the next 1-3 years, ALUR's path will depend on successful execution of its strategic priorities amidst a volatile market environment. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.